Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment engages in the microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segment also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agrochemicals, and diversified specialty chemicals markets. The company has a strategic collaboration agreement with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273; and CellPoint B.V to deliver CAR-T cells to patients at point-of-care. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.